Drug Trial Radar · NCT06859853
A Study to Evaluate MWN109 Injection in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Apr 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Mar 17, 2025
Primary completion
Sep 25, 2025
Study completion Nov 25, 2025
Sponsor
- Lead sponsor
- Shanghai Minwei Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a Phase1, randomized, double-blinded, and placebo-controlled study. In each cohort, enrolled participants will be randomized to receive either placebo or MWN109.
Conditions
- Overweight or Obese
Interventions
PlaceboDrug
Sub cutaneous injection on the abdomen by a qualified member of study staff.
Subcutaneous single and mutiple doseDrug
Sub cutaneous injection on the abdomen by a qualified member of study staff.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Incidence of treatment emergent adverse events (TEAEs) following treatment administrationTime frame: Part A- Up to Day 29; Part B- Up to Day 50 post first dose administration
- Number of participants with change in laboratory parameters following treatment administrationTime frame: Part A- Up to Day 29; Part B- Up to Day 50 post first dose administration
- Number of participants with change in Vital signs following treatment administrationTime frame: Part A- Up to Day 29; Part B- Up to Day 50 post first dose administration
- Incidence of anti-drug antibody (ADA) formation following treatment administrationTime frame: Part A- Up to Day 29; Part B- Up to Day 50 post first dose administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Veritus Research
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.